Vanta Bioscience Ltd
Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]
- Market Cap ₹ 10.8 Cr.
- Current Price ₹ 15.2
- High / Low ₹ 31.3 / 14.7
- Stock P/E
- Book Value ₹ 27.2
- Dividend Yield 0.00 %
- ROCE -4.44 %
- ROE -14.4 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.56 times its book value
Cons
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -39.3% over past five years.
- Company has a low return on equity of -11.5% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 562 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 3.88 | 12.08 | 13.72 | 9.82 | 9.06 | 5.17 | 8.56 | 1.13 | 0.63 | |
| 0.00 | 2.84 | 8.81 | 9.40 | 5.92 | 5.66 | 5.65 | 4.91 | 2.79 | 2.67 | |
| Operating Profit | 0.00 | 1.04 | 3.27 | 4.32 | 3.90 | 3.40 | -0.48 | 3.65 | -1.66 | -2.04 |
| OPM % | 26.80% | 27.07% | 31.49% | 39.71% | 37.53% | -9.28% | 42.64% | -146.90% | -323.81% | |
| 0.00 | 0.05 | 0.23 | 0.11 | 0.02 | 0.17 | 0.63 | 0.05 | 0.04 | 0.04 | |
| Interest | 0.00 | 0.20 | 1.69 | 1.95 | 2.06 | 2.11 | 3.11 | 2.42 | 0.66 | 0.82 |
| Depreciation | 0.00 | 0.57 | 0.71 | 1.19 | 1.25 | 1.32 | 1.25 | 1.24 | 0.44 | 0.44 |
| Profit before tax | 0.00 | 0.32 | 1.10 | 1.29 | 0.61 | 0.14 | -4.21 | 0.04 | -2.72 | -3.26 |
| Tax % | 90.62% | 36.36% | 24.03% | 21.31% | 42.86% | 0.71% | -25.00% | -2.21% | ||
| 0.00 | 0.03 | 0.69 | 0.98 | 0.47 | 0.08 | -4.24 | 0.05 | -2.66 | -3.18 | |
| EPS in Rs | 0.00 | 0.05 | 1.09 | 1.55 | 0.74 | 0.13 | -6.72 | 0.08 | -4.21 | -4.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | -39% |
| 3 Years: | -50% |
| TTM: | -85% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -134% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | -38% |
| 3 Years: | -36% |
| 1 Year: | -32% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | -6% |
| 3 Years: | -11% |
| Last Year: | -14% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3.65 | 5.73 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 6.31 | 7.11 |
| Reserves | 2.50 | 10.86 | 15.93 | 17.13 | 17.60 | 17.68 | 13.43 | 13.48 | 10.82 | 12.21 |
| 7.50 | 11.18 | 13.25 | 14.15 | 17.28 | 20.77 | 25.76 | 25.38 | 30.47 | 30.57 | |
| 0.10 | 1.40 | 2.51 | 4.00 | 5.06 | 5.64 | 6.14 | 7.74 | 8.23 | 6.99 | |
| Total Liabilities | 13.75 | 29.17 | 38.00 | 41.59 | 46.25 | 50.40 | 51.64 | 52.91 | 55.83 | 56.88 |
| 12.95 | 17.49 | 17.90 | 20.76 | 29.39 | 36.12 | 37.40 | 37.87 | 42.43 | 41.82 | |
| CWIP | 0.00 | 2.34 | 3.70 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 4.50 | 3.95 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 | 3.00 |
| 0.80 | 4.84 | 12.45 | 17.83 | 13.86 | 11.28 | 11.24 | 12.04 | 10.40 | 12.06 | |
| Total Assets | 13.75 | 29.17 | 38.00 | 41.59 | 46.25 | 50.40 | 51.64 | 52.91 | 55.83 | 56.88 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| -0.26 | -6.75 | -0.06 | 3.17 | 11.01 | 6.70 | 0.64 | 4.55 | 1.36 | |
| -12.95 | -7.53 | -4.70 | -1.56 | -9.96 | -8.08 | -2.53 | -1.67 | -5.79 | |
| 13.66 | 13.93 | 4.96 | -1.80 | -1.07 | 1.38 | 1.88 | -2.81 | 4.43 | |
| Net Cash Flow | 0.44 | -0.36 | 0.20 | -0.20 | -0.02 | 0.00 | 0.00 | 0.07 | 0.00 |
| Free Cash Flow | -13.21 | -14.21 | -2.54 | 2.82 | 1.15 | -1.35 | -1.89 | 2.88 | -4.43 |
| CFO/OP | -649% | -2% | 73% | 282% | 197% | -133% | 125% | -82% |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 31.04 | 47.14 | 36.18 | 73.59 | 29.01 | 135.55 | 99.78 | 562.04 | |
| Inventory Days | 3,444.69 | 2,409.00 | 2,389.09 | ||||||
| Days Payable | 228.12 | 119.93 | 991.77 | ||||||
| Cash Conversion Cycle | 3,247.61 | 2,336.21 | 36.18 | 73.59 | 29.01 | 135.55 | 99.78 | 1,959.36 | |
| Working Capital Days | 190.03 | 260.76 | 272.95 | 96.27 | 38.27 | 57.19 | -98.50 | -2,687.43 | |
| ROCE % | 2.27% | 8.09% | 8.81% | 6.73% | 5.24% | -2.44% | 5.34% | -4.44% |
Insights
In beta| Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Research & Development (R&D) Expenditure INR Lakhs |
|
||||||||
| Total Headcount (Permanent Employees) Number |
|||||||||
| Unbilled Revenue (Services Under Process/Inventory) INR Lakhs |
|||||||||
| Number of Scientists Number |
|||||||||
Documents
Announcements
- Closure of Trading Window 24 Mar
-
Clarification On Movement In Price
11 Mar - On 11.03.2026, company told BSE it disclosed material information; unaware of cause for 25.02.2026 price movement.
-
Clarification sought from Vanta Bioscience Ltd
25 Feb - Exchange has sought clarification from Vanta Bioscience Ltd on February 25, 2026 with reference to significant movement in price, in order to ensure that investors …
-
Board Meeting Outcome for Outcome Of The Board Meeting - Appointment Of Company Secretary And Compliance Officer
30 Jan - Ms. Pooja Kothari appointed Company Secretary & Compliance Officer effective 30.01.2026.
- Financial Results For The Half Year Ended September 30, 2025 14 Nov 2025
Business Overview:[1][2][3]
a) VBSL conducts R&D, clinical, and pre-clinical studies across genetic, animal, inhalation, and eco-toxicology.
b) It is a preclinical contract research company offering safety assessment services to clients in pharma, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemicals.
c) The company provides risk assessment services for APIs, excipients, extractables, leachables, and impurities arising from manufacturing or product degradation.
d) VBSL also offers expert services to determine health-based exposure limits, including PDE, ADE, and OEL for pharmaceutical manufacturers.